loading page

Euglycemic DKA (euDKA) as a presentation of COVID19
  • +1
  • Bhagwan Dass,
  • Andrew Beck,
  • Cody Holmes,
  • Glenville Morton
Bhagwan Dass
University of Florida

Corresponding Author:bdass98@gmail.com

Author Profile
Andrew Beck
Eglin Air Force Base
Author Profile
Cody Holmes
Eglin Air Force Base
Author Profile
Glenville Morton
Eglin Air Force Base
Author Profile


Euglycemic DKA (euDKA) is a serious side effect associated with SGLT2 inhibitors. We present a case euDKA in a patient on an SGLT-2 inhibitor likely precipitated by COVID-19 infection. We suspect that COVID-19 led to euDKA. We pose the question of whether these medications should be discontinued proactively.
03 Sep 2020Submitted to Clinical Case Reports
15 Sep 2020Assigned to Editor
15 Sep 2020Submission Checks Completed
18 Sep 2020Reviewer(s) Assigned
01 Oct 2020Review(s) Completed, Editorial Evaluation Pending
28 Oct 2020Editorial Decision: Accept